Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL6325038 | 0.90 | NPC1 (0.49) | MAPTLMNASMN1; SMN2KMT2ACYP4Z1 | |
| SCHEMBL7335258 | 0.87 | THRA (0.51) | MAPTLMNASMN1; SMN2KMT2ACYP4Z1 | |
| SCHEMBL4268203 | 0.84 | L3MBTL1 (0.59) | MAPTLMNASMN1; SMN2KMT2ACYP4Z1 | |
| SCHEMBL15955709 | 0.83 | KMT2A (0.60) | MAPTLMNASMN1; SMN2KMT2ACYP4Z1 | |
| SCHEMBL6681547 | 0.82 | HSD17B3 (0.58) | — | |
| SCHEMBL68851 | 0.81 | CYP4Z1 (0.62) | MAPTLMNASMN1; SMN2KMT2ACYP4Z1 | |
| SCHEMBL392939 | 0.81 | GSK3B (0.55) | MAPTLMNASMN1; SMN2KMT2ACYP4Z1 | |
| SCHEMBL8149524 | 0.80 | MAPT (0.55) | MAPTLMNASMN1; SMN2KMT2ACYP4Z1 | |
| Hydrochloric Acid SCHEMBL11655187 | 0.79 | LMNA (0.50) | MAPTLMNASMN1; SMN2KMT2ACYP4Z1 | |
| SCHEMBL6393097 | 0.78 | ALDH1A1 (0.57) | MAPTLMNASMN1; SMN2KMT2ACYP4Z1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| EP-2736330-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019682-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| CN-1063180-C | 5H, 10H-imidazo [1, 2 -a] indeno [1, 2 -e] pyrazin-4-one derivatives, preparation thereof, and drugs containing said derivatives | RHONE POULENC RORER SA (FR) | 2001-03-14 | — | — | CN | disclosed |
| US-5902803-A | 5H,10H-imidazo 1,2-a!indeno 1,2-e!pyrazin-4-one derivatives, preparation thereof, and drugs containing said derivatives | RHONE-POULENC RORER S.A. (FR) | 1999-05-11 | — | — | US | disclosed |
| CN-1180357-A | 5H, 10H-imidazo [1, 2-a ] indeno [1, 2-e ] pyrazin-4-one derivatives, preparation thereof and medicaments containing same | RHONE POULENC RORER SA (FR) | 1998-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315881-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | MAPT 3084/4885LMNA 4009/4885SMN1; SMN2 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.